Kyverna Therapeutics, Inc.

As of June 9, 2025, the technical trend is mildly bearish, with mixed signals from moving averages, MACD, and RSI across different time frames, indicating a lack of strong bullish momentum.

Kyverna Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $45 million and a market cap of $127.93 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -64.92%.

As of Jun 18, Kyverna Therapeutics, Inc. has a market capitalization of 127.93 million and reported net sales of 0.00 million with a net profit of -145.41 million over the latest four quarters. Shareholder's funds were 266.59 million, and total assets were 306.52 million as of Dec 24.